News articles about REGENXBIO (NASDAQ:RGNX) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. REGENXBIO earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5213026758415 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics (marketrealist.com)
- What Investors Should Know about Regenxbio’s Research Pipeline (marketrealist.com)
- Regenxbio Inc (RGNX) SVP Sells $390,000.00 in Stock (americanbankingnews.com)
- How Analysts Rate Regenxbio and Peers in April 2018 (finance.yahoo.com)
- What Investors Should Know about Regenxbio’s Research Pipeline (finance.yahoo.com)
Shares of REGENXBIO stock opened at $34.60 on Monday. The stock has a market cap of $1,102.72, a price-to-earnings ratio of -14.12 and a beta of -1.15. REGENXBIO has a 12-month low of $16.30 and a 12-month high of $42.00.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.20. The firm had revenue of $2.04 million for the quarter. REGENXBIO had a negative net margin of 704.02% and a negative return on equity of 36.48%. equities analysts predict that REGENXBIO will post -2.5 EPS for the current fiscal year.
Several equities analysts recently commented on RGNX shares. Zacks Investment Research upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research note on Friday, March 16th. BidaskClub upgraded shares of REGENXBIO from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 22nd. Raymond James Financial restated a “buy” rating on shares of REGENXBIO in a research note on Friday, January 5th. Morgan Stanley decreased their price target on shares of REGENXBIO from $36.00 to $35.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 14th. Finally, Mizuho started coverage on shares of REGENXBIO in a research note on Monday, February 12th. They issued a “neutral” rating and a $28.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $42.00.
In other news, SVP Patrick J. Christmas sold 10,000 shares of the stock in a transaction dated Wednesday, April 11th. The shares were sold at an average price of $39.00, for a total value of $390,000.00. Following the completion of the transaction, the senior vice president now owns 11,141 shares of the company’s stock, valued at $434,499. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $30.16, for a total transaction of $150,800.00. The disclosure for this sale can be found here. Insiders have sold 85,000 shares of company stock worth $2,690,200 over the last quarter. Corporate insiders own 17.00% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact REGENXBIO (RGNX) Stock Price” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2018/04/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-regenxbio-rgnx-stock-price.html.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.